19 results on '"De Brabanter, G."'
Search Results
2. Effectiveness of different combinations of DMARDs and glucocorticoid bridging in early rheumatoid arthritis: two-year results of CareRA
- Author
-
Stouten, Veerle, Westhovens, Rene, Pazmino, Sofia, De Cock, Diederik, Van der Elst, Kristien, Joly, Johan, Verschueren, Patrick, Maeyaert, B, De Brabanter, G, Devinck, M, Langenaken, C, Lenaerts, J, Corluy, L, Remans, J, Vander Cruyssen, B, Ravelingien, I, Van Essche, E, Vandevyvere, K, Durnez, A, Verbruggen, A, Geens, E, Raeman, F, Joos, R, de Vlam, K, Taelman, V, Vanhoof, J, Coppens, M, Geusens, P, Sileghem, A, Volders, P, Van Den Bosch, F, Verschueren, P, Westhovens, R, and Public Health Sciences more...
- Subjects
Male ,Time Factors ,early rheumatoid arthritis ,Severity of Illness Index ,OPPORTUNITY ,WINDOW ,law.invention ,Arthritis, Rheumatoid ,Prednisone/administration & dosage ,Antirheumatic Agents/administration & dosage ,Joints/diagnostic imaging ,Randomized controlled trial ,law ,Prednisone ,Pharmacology (medical) ,Prospective Studies ,Leflunomide ,treatment ,glucocorticoids ,TREATMENT STRATEGIES ,Middle Aged ,Prognosis ,OPEN-LABEL ,Treatment Outcome ,TARGET ,Antirheumatic Agents ,Rheumatoid arthritis ,Arthritis, Rheumatoid/diagnosis ,Prednisolone ,Drug Therapy, Combination ,Female ,TRIAL ,DMARDs (synthetic) ,Life Sciences & Biomedicine ,Immunosuppressive Agents ,medicine.drug ,medicine.medical_specialty ,REMISSION INDUCTION ,effectiveness ,Leflunomide/administration & dosage ,PREDNISOLONE ,Drug Administration Schedule ,methotrexate ,Sulfasalazine/administration & dosage ,Rheumatology ,Sulfasalazine ,Internal medicine ,medicine ,Humans ,Adverse effect ,Immunosuppressive Agents/administration & dosage ,Glucocorticoids ,Science & Technology ,Dose-Response Relationship, Drug ,business.industry ,Glucocorticoids/administration & dosage ,medicine.disease ,Radiography ,Regimen ,Joints ,business ,Follow-Up Studies - Abstract
ObjectivesTo investigate whether MTX should be combined with an additional DMARD and bridging glucocorticoids as initial treatment for patients with early RA to induce an effective long-term response.MethodsThe Care in early RA study is a two-year investigator-initiated pragmatic multicentre randomized trial. Early RA patients, naïve to DMARDs and glucocorticoids, were stratified based on prognostic factors. High-risk patients were randomized to COBRA-Classic (n = 98): MTX, sulfasalazine, prednisone step-down from 60 mg; COBRA-Slim (n = 98): MTX, prednisone step-down from 30 mg; or COBRA-Avant-Garde (n = 93): MTX, leflunomide, prednisone step-down from 30 mg. Low-risk patients were randomized to COBRA-Slim (n = 43); or Tight Step Up (TSU) (n = 47): MTX without prednisone. Clinical/radiological outcomes at year 2, sustainability of response, safety and treatment adaptations were assessed.ResultsIn the high-risk group 71/98 (72%) patients achieved a DAS28-CRP < 2.6 with COBRA-Slim compared with 64/98 (65%) with COBRA-Classic and 69/93 (74%) with COBRA-Avant-Garde (P = 1.00). Other clinical/radiological outcomes and sustainability of response were similar. COBRA-Slim treatment resulted in less therapy-related adverse events compared with COBRA-Classic (P = 0.02) or COBRA-Avant-Garde (P = 0.005). In the low-risk group, 29/43 (67%) patients on COBRA-Slim and 34/47 (72%) on TSU achieved a DAS28-CRP < 2.6 (P = 1.00). On COBRA-Slim, low-risk patients had lower longitudinal DAS28-CRP scores over 2 years, a lower need for glucocorticoid injections and a comparable safety profile compared with TSU.ConclusionAll regimens combining DMARDs with glucocorticoids were effective for patients with early RA up to 2 years. The COBRA-Slim regimen, MTX monotherapy with glucocorticoid bridging, provided the best balance between efficacy and safety, irrespective of patients’ prognosis.Trial registrationClinicalTrials.gov, http://www.clinicaltrials.gov, NCT01172639. more...
- Published
- 2019
- Full Text
- View/download PDF
Catalog
3. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16□weeks of treatment: the CareRA trial
- Author
-
Verschueren, P, De Cock, D, Corluy, L, Joos, R, Langenaken, C, Taelman, V, Raeman, F, Ravelingien, I, Vandevyvere, K, Lenaerts, J, Geens, E, Geusens, P, Vanhoof, J, Durnez, A, Remans, J, Vander Cruyssen, B, Van Essche, E, Sileghem, A, De Brabanter, G, Joly, J, Meyfroidt, S, Van der Elst, K, Westhovens, R, Maeyaert, B, Devinck, M, Verbruggen, A, de Vlam, K, Coppens, M, Volders, P, and Van Den Bosch, F more...
- Published
- 2015
- Full Text
- View/download PDF
4. Personal attributes as determinants of timely care in rheumatoid arthritis
- Author
-
Esselens, G H, De Brabander, A, Ovaere, L, De Brabanter, G, Moons, P, and Westhovens, R
- Published
- 2006
5. Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: week 16 results from the randomized multicenter CareRA trial
- Author
-
Verschueren, P., de Cock, D., Corluy, L., Joos, R., Langenaken, C., Taelman, V., Raeman, F., Ravelingien, I., Vandevyvere, K., Lenaerts, J., Geens, E., Geusens, P., Vanhoof, J., Durnez, A., Remans, J., vander Cruyssen, B., van Essche, E., Sileghem, A., de Brabanter, G., Joly, J., van der Elst, K., Meyfroidt, S., Westhovens, R., CareRA study group, the, RS: CAPHRI School for Public Health and Primary Care, RS: CAPHRI - R3 - Functioning, Participating and Rehabilitation, Interne Geneeskunde, Public Health Sciences, and Cell Biology and Histology more...
- Subjects
Glucocorticoids/therapeutic use ,Male ,Time Factors ,Arthritis ,Antirheumatic Agents/therapeutic use ,Cobra ,Severity of Illness Index ,THERAPY ,law.invention ,Arthritis, Rheumatoid ,Randomized controlled trial ,Prednisone ,law ,Immunology and Allergy ,Prospective Studies ,skin and connective tissue diseases ,Prospective cohort study ,computer.programming_language ,biology ,Middle Aged ,Prognosis ,EULAR RECOMMENDATIONS ,C-Reactive Protein ,Treatment Outcome ,Antirheumatic Agents ,Area Under Curve ,Female ,Research Article ,medicine.drug ,Adult ,musculoskeletal diseases ,medicine.medical_specialty ,Methotrexate/therapeutic use ,Arthritis, Rheumatoid/blood ,Immunology ,AMERICAN-COLLEGE ,Drug Administration Schedule ,CLASSIFICATION ,C-Reactive Protein/analysis ,Rheumatology ,Internal medicine ,MANAGEMENT ,medicine ,Humans ,Rheumatoid factor ,Glucocorticoids ,Aged ,COMBINATION-TREATMENT STRATEGIES ,Dose-Response Relationship, Drug ,business.industry ,TIGHT CONTROL ,C-reactive protein ,REMISSION ,medicine.disease ,Methotrexate ,MODIFYING ANTIRHEUMATIC DRUGS ,biology.protein ,Physical therapy ,FOLLOW-UP ,business ,computer ,Biomarkers/blood ,Biomarkers - Abstract
Introduction Considering a lack of efficacy data in patients with early rheumatoid arthritis (eRA) presenting without classical markers of poor prognosis, we compared methotrexate (MTX) with or without step-down glucocorticoids in the CareRA trial. Methods Disease-modifying antirheumatic drug–naïve patients with eRA were stratified into a low-risk group based on prognostic markers that included non-erosiveness, anti–citrullinated protein antibodies and rheumatoid factor negativity and low disease activity (Disease Activity Score in 28 joints based on C-reactive protein (DAS28(CRP)) ≤3.2). Patients were randomized to 15 mg of MTX weekly (MTX with tight step-up (MTX-TSU)) or 15 mg of MTX weekly with prednisone bridging, starting at 30 mg and tapered to 5 mg daily from week 6 (COmbinatie therapie bij Reumatoïde Artritis (COBRA Slim)). A TSU approach was applied. Outcomes assessed were DAS28(CRP)-determined remission, cumulative disease activity, Health Assessment Questionnaire (HAQ) scores and adverse events (AEs) after 16 treatment weeks. Results We analyzed 43 COBRA Slim and 47 MTX-TSU patients and found that 65.1% in the COBRA Slim group and 46.8% in the MTX-TSU group reached remission (P = 0.081). Mean ± standard deviation area under the curve values of DAS28(CRP) were 13.84 ± 4.58 and 11.18 ± 4.25 for the MTX-TSU and COBRA Slim patients, respectively (P = 0.006). More COBRA Slim patients had an HAQ score of 0 (51.2% versus 23.4%, P = 0.006) at week 16. Therapy-related AEs between groups did not differ. Conclusion In patients with low-risk eRA, MTX with step-down glucocorticoid bridging seems more efficacious than MTX step-up monotherapy, with a comparable number of AEs observed over the first 16 treatment weeks. Trial registration EU Clinical Trials Register Identifier: EudraCT number 2008-007225-39. Registered 5 November 2008. Electronic supplementary material The online version of this article (doi:10.1186/s13075-015-0611-8) contains supplementary material, which is available to authorized users. more...
- Published
- 2015
- Full Text
- View/download PDF
6. An induction or flare of arthritis and/or sacroiliitis by vedolizumab in inflammatory bowel disease: a case series
- Author
-
Varkas, G, primary, Thevissen, K, additional, De Brabanter, G, additional, Van Praet, L, additional, Czul-gurdian, F, additional, Cypers, H, additional, De Kock, J, additional, Carron, P, additional, De Vos, M, additional, Hindryckx, P, additional, Arts, J, additional, Vanneuville, I, additional, Schoenaers, P, additional, Claerhout, B, additional, Abreu, M, additional, Van den Bosch, F, additional, and Elewaut, D, additional more...
- Published
- 2016
- Full Text
- View/download PDF
7. Eular workshop on Rheumatology Research: Noordwijkerhout February 1982
- Author
-
Bjelle, A., Cedergren, B., Wählby, L., Boerbooms, A. P. Th., Geerdink, P. J., van de Putte, L. B. A., Ouweland, F. A. M., Buchanan, R. R. C., Morgan, A., Staines, N. A., Venables, P. J. W., Maini, R. N., Bucknall, R. C., Bacon, P. A., Jones, J. Verrier, Leirisalo, M., Laitinen, O., Bühring, M., Rosak, C., Stöckle, W., Magnet, W., Catogio, L. J., Bernstein, R. M., Black, C. M., Hughes, G. R. V., Maddison, P. J., Charles P. J., Venables P. J. W., Tung Yi., Buchanan R. C., Maini R. N., Deicher, H., Weißbarth, E., Zeller, J., Baruth, B., Delbarre, F., de Gery, A., Kahan, A., de Vries, E., van der Veen, C. J. P., van der Weij, J. P., Klein, F., de Bruijn, A. M., Cats, A., Dreher, R., Coworkers, Duclos, M., Peter, H., Zeidler, H., Rieber, P., Pichler, J., Limany, W., Dunn, N., Hurst, N. P., Denholm, E., Nuki, G., Ebringer, A., Hayes, J., Cowling, P., Ebringer, R., Egeland, T., Forre, Ø., Festen, J. J. M., Kuipers, F. H., Schaars, A. H., Førre, Ø., Waalen, K., Mellbye, O. J., Froebel, K., Lewis, D., Sturrock, R. D., Goldschmeding, R., Limburg, P. C., Pastoor, G. W., Houtman, P. M., Kallenberg, C. G. M., Halberg, P., Lorenzen, I., Bennedsen, J., Rhodes, J. M., Hall, N. D., Eales, L. -J., Blake, D. R., Hunneyball, I. M., Helmke, K., Boeder, T., Teuber, J., Hermanns, P., Veys, E. M., Verbruggen, G., Horsfall, A. C., Mumford, P. A., Schrieber, L., Huber, O., Kluin-Nelemans, H., Vernooy, J., Meyling, F. Gmelig, Derksen, R., Kater, L., Hurst N. P., Nuki G., Husby, G., Gran, J. T., Thorsby, E., Johnson, G. D., Bainbridge, D. R., Holborow, E. J., Bubel, M., Goddard, D. H., Jonsson, J., Norberg, R., Schilling, W., Kalden, R., Leitner, O., Manger, B., Beck, A., Koch, B., de Jong, M. C. J. M., Walstra, T., van der Meulen, J., Kávai, M., Bányai, A., Zsindely, A., Sonkoly, I., Szegedi, Gy., Klareskog, L., Forsum, U., Scheynius, A., Kabelitz, D., Wigzell, H., Koivuranta, P., Repo, H., Kiistala, U., Österman, P., Konttinen, Y., Friman, C., Tolvanen, E., Johansson, E., Konttinen, Y. T., Reitamo, S., Seppä, A., Malmström, M., Lindström, F., Hellquist, H., Olofsson, J., Maddison, PJ., Black, CM., Jayson, MIV, Batchelor, J. R., Walsh, Kl., Bernstein, RM, Catoggio, LJ., Holland, CD., Hughes, GRV, Mbuyi, J. M., Dequeker, J., Förre Ö, Johnsen, W., Meijer, C. J. L. M., de Graaf-Reitsma, C., Lafeber, G. J. M., Meyer, O., Borda-Oriarte, O., Haïm, T., Ryckewaert, A., Mielants, H., Van Steenkiste, M., De Langhe, J., Buchanan, R. C., Moutsopoulos, M., Hooks, J., Mumford, P., Patel, V., Panayi, G. S., Piatier-Tonneau, D., Mach, P. S., Plater-Zyberk, C., Clarke, M., Raeman, F., De Cock, W., Leempoels, J., De Cree, J., Verhaegen, H., Ranki, A., Paavonen, T., Kankaanpää, U., Nilsson, E., Biberfeld, G., Room, G., Saal, J. G., Frank, F., Rauteenstrauch, H., Hadam, M., Fritz, P., Laschner, W., Scheper, R. J., von Blomberg-van der Flier, B. M. E., Boerrigter, G. H., van Bruynzeel, D., van Dinther-Janssen, A. C. H. M., Simon, K. H., Schmidt, R. E., Erhardt, C. C., Melsom, R. D., McCarthy, J., Smeenk, R., Van der Lelij, G., Aarden, L., Staite, N. D., Stierle, H. E., Brown, K. A., Perry, J. D., Swaak, A. J. G., Groenwold, J., Smeenk, R. J. T., Toenes, G. H., Edel, H. H., Eggert, K., Held, E., Hübner, F. K., Schattenkirchner, M., Wegelius, O., Tron, F., Jacob, L., Bach, J. F., Lens, J. W., van den Berg, W. B., van Rijswijk, M. H., van Leeuwen, M. A., van der Giessen, M., The, T. H., van Venrooij, W. J., van Eekelen, C. A. G., Habets, W. J. A., Salden, M. H. L., de Rooij, D. J., Van Wanghe, P., Hermanns, Ph., Van Bruwaene, Ph., De Brabanter, G., De Landsheere, D., Immesoete, C., Walravens, M. J. F., Stevens, E., Warnatz, H., Lemm, G., Wiik, A., Petersen, J., Permin, H., Wollheim, F. A., Carlsson, J., Forsgren, A., Pettersson, H., Youinou, P., Miossec, P., and Le Goff, P. more...
- Published
- 1982
- Full Text
- View/download PDF
8. THU0117 Low-Risk Patients Also Benefit from Remission Induction Treatment in Early Rheumatoid Arthritis: Week 52 Results from the Carera Trial
- Author
-
De Cock, D., primary, Corluy, L., additional, Joos, R., additional, Langenaken, C., additional, Taelman, V., additional, Raeman, F., additional, Ravilingien, I., additional, Vandevyvere, K., additional, Lenaerts, J., additional, Geens, E., additional, Geusens, P., additional, Vanhoof, J., additional, Durnez, A., additional, Remans, J., additional, Vander Cruyssen, B., additional, Van Essche, E., additional, Sileghem, A., additional, De Brabanter, G., additional, Joly, J., additional, Meyfroidt, S., additional, Van der Elst, K., additional, Westhovens, R., additional, and Verschueren, P., additional more...
- Published
- 2015
- Full Text
- View/download PDF
9. OP0180 Remission Induction with Dmard Combinations and Glucocorticoids is not Superior to Remission Induction with MTX Monotherapy and Glucocorticoids: Week 52 Results of the High-Risk Group from the Carera Trial
- Author
-
Verschueren, P., primary, De Cock, D., additional, Corluy, L., additional, Joos, R., additional, Langenaken, C., additional, Taelman, V., additional, Raeman, F., additional, Ravilingien, I., additional, Vandevyvere, K., additional, Lenaerts, J., additional, Geens, E., additional, Geusens, P., additional, Vanhoof, J., additional, Durnez, A., additional, Remans, J., additional, Vander Cruyssen, B., additional, Van Essche, E., additional, Sileghem, A., additional, De Brabanter, G., additional, Joly, J., additional, Van der Elst, K., additional, Meyfroidt, S., additional, and Westhovens, R., additional more...
- Published
- 2015
- Full Text
- View/download PDF
10. AB0814 The BEPAS Cohort: A Prospective Cohort of Psoriatic Arthritis in Belgium: Study Design and Baseline Characteristics of the 461 Recruited Patients
- Author
-
de Vlam, K., primary, Lories, R., additional, Steinfeld, S., additional, van den Bosch, F., additional, Nzeusseu Toukap, A., additional, Malaise, M., additional, Taelman, V., additional, Van Bruwaene, F., additional, Vanden Berghe, M., additional, Joos, R., additional, Lenaerts, J., additional, Geussens, P., additional, Dalli'Armellina, S., additional, Peene, I., additional, De Brabanter, G., additional, Van Den Berghe, M., additional, Qu, J., additional, Maertens, M., additional, and Leroi, H., additional more...
- Published
- 2015
- Full Text
- View/download PDF
11. T-Cell Subpopulations in Peripheral Blood and Synovial Fluid in Rheumatic Diseases
- Author
-
VEYS, E.M., primary, DE BRABANTER, G., additional, DE LANDSHEERE, D., additional, HERMANNS, P., additional, IMMESOETE, C., additional, JOOS, R., additional, MIELANTS, H., additional, SALVADOR-MOLINA, C., additional, STAPPAERTS, G., additional, and VERBRUGGEN, G., additional more...
- Published
- 1984
- Full Text
- View/download PDF
12. An induction or flare of arthritis and/or sacroiliitis by vedolizumab in inflammatory bowel disease: a case series.
- Author
-
Varkas, G., Thevissen, K., De Brabanter, G., Van Praet, L., Czul-gurdian, F., Cypers, H., De Kock, J., Carron, P., De Vos, M., Hindryckx, P., Arts, J., Vanneuville, I., Schoenaers, P., Claerhout, B., Abreu, M., Van den Bosch, F., and Elewaut, D. more...
- Subjects
ANKYLOSING spondylitis ,ARTHRITIS ,CROHN'S disease ,GASTROINTESTINAL agents ,MONOCLONAL antibodies ,ULCERATIVE colitis - Abstract
Background: In inflammatory bowel disease (IBD), a new biological therapy has recently been approved. Vedolizumab is a humanised IgG1 monoclonal antibody to α4β7 integrin that modulates gut lymphocyte trafficking. Although an exclusively local effect of vedolizumab could be expected based on the restricted presence of the α4β7-mucosal vascular addressin cell adhesion molecule 1 complex in the gut, past combined success with anti-tumour necrosis factor, and previous demonstration of α4β7 integrin in the joint, led to the expectation of a therapeutic efficacy in spondyloarthritis. Nonetheless, the effect of vedolizumab on extraintestinal manifestations-and especially the joint-has not been reported so far.Case Report: A series of five patients with IBD who were treated with vedolizumab and promptly developed new onset or exacerbation of sacroiliitis or arthritis are reported.Conclusions: Vedolizumab therapy does not seem to show any efficacy in and might even induce arthritis and/or sacroiliitis. However, larger cohort studies are needed to provide information on the prevalence, the evolution and underlying mechanism. [ABSTRACT FROM AUTHOR] more...- Published
- 2017
- Full Text
- View/download PDF
13. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial
- Author
-
Verschueren, P, primary, De Cock, D, additional, Corluy, L, additional, Joos, R, additional, Langenaken, C, additional, Taelman, V, additional, Raeman, F, additional, Ravelingien, I, additional, Vandevyvere, K, additional, Lenaerts, J, additional, Geens, E, additional, Geusens, P, additional, Vanhoof, J, additional, Durnez, A, additional, Remans, J, additional, Vander Cruyssen, B, additional, Van Essche, E, additional, Sileghem, A, additional, De Brabanter, G, additional, Joly, J, additional, Meyfroidt, S, additional, Van der Elst, K, additional, and Westhovens, R, additional more...
- Published
- 2014
- Full Text
- View/download PDF
14. THU0121 Comparison of MTX Therapy with or without A Moderate Dose Glucocorticoid Bridging Scheme in Early Rheumatoid Arthritis Patients Lacking Classical Poor Prognostic Markers: Week 16 Results from the Randomized Multicenter Carera Trial
- Author
-
De Cock, D., primary, Westhovens, R., additional, Corluy, L., additional, Joos, R., additional, Langenaken, C., additional, Taelman, V., additional, Raeman, F., additional, Ravelingien, I., additional, Vandevyvere, K., additional, Lenaerts, J., additional, Geens, E., additional, Geusens, P., additional, Vanhoof, J., additional, Durnez, A., additional, Remans, J., additional, Vander Cruyssen, B., additional, Van Essche, E., additional, Sileghem, A., additional, De Brabanter, G., additional, Joly, J., additional, Meyfroidt, S., additional, Van der Elst, K., additional, and Verschueren, P., additional more...
- Published
- 2014
- Full Text
- View/download PDF
15. THU0137 Associated with A Glucocorticoid Bridging Scheme, Methotrexate is as Effective Alone as in Combination with Other DMARDS for Early Rheumatoid Arthritis, with Fewer Reported Side Effects: 16 Weeks Remission Induction Data from the Carera Trial
- Author
-
Verschueren, P., primary, De Cock, D., additional, Corluy, L., additional, Joos, R., additional, Langenaken, C., additional, Taelman, V., additional, Raeman, F., additional, Ravelingien, I., additional, Vandevyvere, K., additional, Lenaerts, J., additional, Geens, E., additional, Geusens, P., additional, Vanhoof, J., additional, Durnez, A., additional, Remans, J., additional, Vander Cruyssen, B., additional, Van Essche, E., additional, Sileghem, A., additional, De Brabanter, G., additional, Joly, J., additional, Meyfroidt, S., additional, Van der Elst, K., additional, and Westhovens, R., additional more...
- Published
- 2014
- Full Text
- View/download PDF
16. Comparison of the Clinical Expression of Patients with Ankylosing Spondylitis from Europe and Latin America
- Author
-
BENEGAS, MARIANA, MUÑOZ-GOMARIZ, ELISA, FONT, PILAR, BURGOS-VARGAS, RUBEN, CHAVES, JOSÉ, PALLEIRO, DANIEL, MALDONADO COCCO, JOSÉ, GUTIÉRREZ, MIGUEL, SÁENZ, RICARDO, STECKMEN, IVAN, RILLO, OSCAR, MULERO, JUAN, SAMPAIO-BARROS, PERCIVAL, BARCELOS, ANABELA, VANDER CRUYSSEN, BERT, VAZQUEZ-MELLADO, JANITZIA, COLLANTES ESTEVEZ, EDUARDO, Alvarellos, A, Asnal, C, Barreira, JC, Bernard Medina, AG, Bertolo, MB, Bianchi, WA, Bonfiglioli, R, Carneiro, S, Carvalho, HMS, Casado, GC, Casasola Vargas, J, Castro da Rocha, FA, Chacón, RL, Costa, IP, Duarte, AP, Espinoza-Villalpando, J, Esteva, MH, Fuentealba, C, Granados, Y, Huerta-Sil, G, Keiserman, M, Kohem, CL, Leite, NH, Lima, SAL, Maldonado-Cocco, JA, Meirelles, ES, Menin, R, Neira, O, Paira, S, Pimentel, F, Pinheiro, M, Polito, E, Resende, G, Ribeiro, SLE, Rillo, OL, Santiago, MB, Santos, H, Scherbarth, H, Sauma, MFLC, Skare, TL, Sousa, E, Spangenberg, E, Valin, V, Vera, C, Verdejo, U, Vieira, WP, Wong, R, Ackerman, C., Badot, V., Bastien, P., Berghs, H., Bonnet, V., Bouchez, B., Boutsen, Y., Brasseur, J-P., Coigne, E., Coppens, M., Corluy, L., Cornet, T.F., Coutellier, P., Daens, S., Silvano Dall’, A., Daumerie, F., De Brabanter, G., De Decker, V., Declerck, K., Dhondt, E., Di Romana, S., Docquier, C., Duckerts, R., Dujardin, L., Engelbeen, J-P., Fernandez-Lopez, D., Focan-Henrard, D., Fontaine, M-A., Francois, D., Geusens, P., Ghyselen, G., Goemaere, S., Gyselbrecht, L., Halleux, R., Heuse, E., Heylen, A., Huynen-Jeugmans, A-M., Immesoete, C., Janssens, X., Jardinet, D., Joos, R., Kruithof, E., Langenaken, C., Leens, C., Lefebvre, D., Lefebvre, S., Lenaerts, J., Luyten, F., Maenaut, K., Maertens, M., Maeyaert, B., Mielants, H., Mindlin, A., Moris, M., Nzeusseu, A., Pater, C., Peretz, A., Praet, J., Qu, J., Raeman, F., Reychler, R., Ronsmans, I., Sarlet, N., Schatteman, G., Sileghem, A., Stappaerts, G., Stasse, P., Taelman, V., Tant, L., Toussaint, F., Van Den Bossche, N., Van Mullen, X., Van Wanghe, P., Vanden Berghe, M., Vanden Berghe, M., Vanhoof, J., Verbruggen, A., Verbruggen, L., Verdickt, W., Volders, P., Vroninks, P., Westhovens, R., Williame, L., Wouters, M., Zmierczak, H.G., Collantes Estévez, E., Zarco Montejo, P., González Fernández, C., Marañón, H.G., Mulero Mendoza, J., Torre Alonso, J.C., Monte Naranco, H., Fernández Sueiro, J.L., Canalejo, H.J., Gratacós Masmitjá, J., Juanola Roura, X., Batlle Gualda, E., Fernández Dapica, P., Ferrando, E., Brito Brito, M.E., Cuende Quintana, E., Vázquez Galeano, C., Calero Secall, E., Romero Ramos, M.J., Jiménez Ubeda, E., Rodriguez Lozano, C., García López, A., Fernández Prada, M., Queiro Silva, R., Moreno Ruzafa, E., Judez Navarro, E., Más, A.J., Medrano Le Quement, C., Ornilla, E., Montilla Morales, C., Pujol Busquets, M., Clavaguera Poch, T., and Fernández Espartero, M.C. more...
- Abstract
Objective.To compare the clinical, demographic, and serologic characteristics and the treatment of patients diagnosed with ankylosing spondylitis (AS) from Europe (EU) and Latin America (LA).Methods.We included 3439 patients from national registries: the Spanish Registry of Spondyloarthritis (REGISPONSER), the Belgian registry (ASPECT), and the Latin American Registry of Spondyloarthropathies (RESPONDIA). We selected patients with diagnosis of AS who met the modified New York classification criteria. Demographic, clinical, disease activity, functional, and metrological measurement data were recorded. Current treatment was recorded. The population was classified into 2 groups: patients with disease duration < 10 years and those with disease duration ≥ 10 years. A descriptive and comparative analysis of variables of both groups was carried out.Results.There were 2356 patients in EU group and 1083 in LA group. Prevalence of HLA-B27 was 71% in LA group and 83% in EU group (p < 0.001). We found a greater frequency of peripheral arthritis and enthesitis (p < 0.001) in the LA population; prevalence of arthritis was 57% in LA and 42% in EU, and for enthesitis, 54% and 38%. Except for treatment with anti-tumor necrosis factor (anti-TNF), the use of nonsteroidal antiinflammatory drugs (NSAID), corticosteroids, and disease-modifying antirheumatic drugs (DMARD), and the association of anti-TNF and methotrexate use showed a significant difference (p < 0.001) in the 2 populations.Conclusion.The principal differences in the clinical manifestations of patients with AS from EU and LA were the greater frequency of peripheral arthritis and enthesitis in LA group, the higher percentage of HLA-B27 in EU group, and the form of treatment, with a greater use of NSAID, steroids, and DMARD in the LA group. more...
- Published
- 2012
- Full Text
- View/download PDF
17. Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1-year results of CareRA, a randomised pragmatic open-label superiority trial.
- Author
-
Verschueren P, De Cock D, Corluy L, Joos R, Langenaken C, Taelman V, Raeman F, Ravelingien I, Vandevyvere K, Lenaerts J, Geens E, Geusens P, Vanhoof J, Durnez A, Remans J, Vander Cruyssen B, Van Essche E, Sileghem A, De Brabanter G, Joly J, Meyfroidt S, Van der Elst K, and Westhovens R more...
- Subjects
- Adult, Aged, Antirheumatic Agents adverse effects, Arthritis, Rheumatoid blood, C-Reactive Protein metabolism, Drug Therapy, Combination adverse effects, Female, Glucocorticoids administration & dosage, Glucocorticoids adverse effects, Humans, Isoxazoles therapeutic use, Leflunomide, Male, Methotrexate adverse effects, Middle Aged, Prednisone administration & dosage, Prednisone adverse effects, Prognosis, Remission Induction, Risk Factors, Severity of Illness Index, Sulfasalazine therapeutic use, Antirheumatic Agents therapeutic use, Arthritis, Rheumatoid drug therapy, Glucocorticoids therapeutic use, Methotrexate therapeutic use, Prednisone therapeutic use
- Abstract
Objectives: Combining disease-modifying antirheumatic drugs (DMARDs) with glucocorticoids (GCs) is an effective treatment strategy for early rheumatoid arthritis (ERA), yet the ideal schedule and feasibility in daily practice are debated. We evaluated different DMARD combinations and GC remission induction schemes in poor prognosis patients; and methotrexate (MTX) with or without GC remission induction in good prognosis patients, during the first treatment year., Methods: The Care in ERA (CareRA) trial is a 2-year investigator-initiated randomised pragmatic open-label superiority trial comparing remission induction regimens in a treat-to-target approach. DMARD-inexperienced patients with ERA were stratified into a high-risk or low-risk group based upon presence of erosions, disease activity, rheumatoid factor and anticitrullinated protein antibodies. High-risk patients were randomised to a COBRA Classic (MTX + sulfasalazine + prednisone step-down from 60 mg), COBRA Slim (MTX + prednisone step-down from 30 mg) or COBRA Avant Garde (MTX + leflunomide + prednisone step-down from 30 mg) scheme. Low-risk patients were randomised to MTX tight step-up (MTX-TSU) or COBRA Slim. Primary outcome was the proportion of patients in 28 joint disease activity score calculated with C-reactive protein remission at week 52 in an intention-to-treat analysis. Secondary outcomes were safety and effectiveness (ClinicalTrial.gov identifier NCT01172639)., Results: 98 COBRA Classic, 98 COBRA Slim (high risk), 93 COBRA Avant Garde, 47 MTX-TSU and 43 COBRA Slim (low risk) patients were evaluated. Remission was achieved in 64.3% (63/98) COBRA Classic, 60.2% (59/98) COBRA Slim (high risk) and 62.4% (58/93) COBRA Avant Garde patients at W52 (p=0.840); and in 57.4% (27/47) MTX-TSU and 67.4% (29/43) COBRA Slim (low risk) patients (p=0.329). Less adverse events occurred per patient with COBRA Slim (high risk) compared with COBRA Classic or COBRA Avant Garde (p=0.038). Adverse events were similar in MTX-TSU and COBRA Slim (low risk) patients (p=0.871). At W52, 76.0% patients were on DMARD monotherapy, 5.2% used GCs and 7.5% biologicals., Conclusions: MTX with a moderate-dose GC remission induction scheme (COBRA Slim) seems an effective, safe, low-cost and feasible initial treatment strategy for patients with ERA regardless of their prognostic profile, provided a treat-to-target approach is followed., Trial Registration Numbers: EudraCT-number 2008-007225-39 and NCT01172639; Results., (Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.) more...
- Published
- 2017
- Full Text
- View/download PDF
18. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial.
- Author
-
Verschueren P, De Cock D, Corluy L, Joos R, Langenaken C, Taelman V, Raeman F, Ravelingien I, Vandevyvere K, Lenaerts J, Geens E, Geusens P, Vanhoof J, Durnez A, Remans J, Vander Cruyssen B, Van Essche E, Sileghem A, De Brabanter G, Joly J, Meyfroidt S, Van der Elst K, and Westhovens R more...
- Subjects
- Adult, Aged, Arthritis, Rheumatoid diagnosis, Drug Therapy, Combination methods, Early Medical Intervention, Female, Humans, Induction Chemotherapy methods, Leflunomide, Male, Middle Aged, Risk Assessment, Severity of Illness Index, Treatment Outcome, Antirheumatic Agents therapeutic use, Arthritis, Rheumatoid drug therapy, Glucocorticoids therapeutic use, Isoxazoles therapeutic use, Methotrexate therapeutic use, Prednisone therapeutic use, Sulfasalazine therapeutic use
- Abstract
Objectives: To compare the efficacy and safety of intensive combination strategies with glucocorticoids (GCs) in the first 16 weeks (W) of early rheumatoid arthritis (eRA) treatment, focusing on high-risk patients, in the Care in early RA trial., Methods: 400 disease-modifying antirheumatic drugs (DMARD)-naive patients with eRA were recruited and stratified into high risk or low risk according to classical prognostic markers. High-risk patients (n=290) were randomised to 1/3 treatment strategies: combination therapy for early rheumatoid arthritis (COBRA) Classic (methotrexate (MTX)+ sulfasalazine+60 mg prednisone tapered to 7.5 mg daily from W7), COBRA Slim (MTX+30 mg prednisone tapered to 5 mg from W6) and COBRA Avant-Garde (MTX+leflunomide+30 mg prednisone tapered to 5 mg from W6). Treatment modifications to target low-disease activity were mandatory from W8, if desirable and feasible according to the rheumatologist. The primary outcome was remission (28 joint disease activity score calculated with C-reactive protein <2.6) at W16 (intention-to-treat analysis). Secondary endpoints were good European League Against Rheumatism response, clinically meaningful health assessment questionnaire (HAQ) response and HAQ equal to zero. Adverse events (AEs) were registered., Results: Data from 98 Classic, 98 Slim and 94 Avant-Garde patients were analysed. At W16, remission was reached in 70.4% Classic, 73.6% Slim and 68.1% Avant-Garde patients (p=0.713). Likewise, no significant differences were shown in other secondary endpoints. However, therapy-related AEs were reported in 61.2% of Classic, in 46.9% of Slim and in 69.1% of Avant-Garde patients (p=0.006)., Conclusions: For high-risk eRA, MTX associated with a moderate step-down dose of GCs was as effective in inducing remission at W16 as DMARD combination therapies with moderate or high step-down GC doses and it showed a more favourable short-term safety profile., Eudract Number: 2008-007225-39., (Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.) more...
- Published
- 2015
- Full Text
- View/download PDF
19. Peripheral blood T lymphocytes subpopulations in HLA-B7 related rheumatic diseases: ankylosing spondylitis and reactive synovitis.
- Author
-
Veys EM, Verbruggen G, Hermanns P, Mielants H, Van Bruwaene P, De Brabanter G, De Landsheere D, and Immesoete C
- Subjects
- Adult, Antibodies, Monoclonal, HLA-B27 Antigen, Humans, Leukocyte Count, Middle Aged, Arthritis, Rheumatoid immunology, HLA Antigens analysis, Spondylitis, Ankylosing immunology, Synovitis immunology, T-Lymphocytes classification
- Abstract
The etiology of B lymphocyte hyperactivity in ankylosing spondylitis (AS) and in reactive synovitis is unknown and data available on the cellular immune system are controversial. We therefore evaluated peripheral blood T cell populations in AS patients and patients with reactive synovitis (RS) using monoclonal antibodies, previously shown to react with all T cells (OKT3), the inducer-helper T cell subset (OKT4) and the suppressor-cytotoxic T cell subset (OKT8). Results were compared with a normal control group and a group of rheumatoid arthritis (RA) patients. In AS an increase of OKT4+ cells was found, but the total number of T helper-inducer cells in peripheral blood was not different from the normal group and the group of patients with RS. Contrary to the results found in RA, where the helper-inducer/suppressor-cytotoxic ratio (OKT4+/OKT8+) was significantly increased, the immunoregulatory ratio in AS and in RS was normal suggesting another mechanism leading to B cell hyperactivity than in RA. more...
- Published
- 1983
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.